US RAC recommends approval of clinical protocol for first human test of ViroMed's VM202

Viromed, a local biotech company, said on August 17 that the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH) has voted unanimously that the first human clinical study of ViroMed' gene therapy, a new naked DNA vector, for the treatment of cardiovascular disease should be carried out under the protocol proposed by the company.

The RAC serves as an advisory c...